ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2484

Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
Abstract Number: 2485

Prevalence of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease
Abstract Number: 2486

In vitro antifibrotic effects of nerandomilast on cell types relevant to intestinal remodeling and fibrosis in systemic sclerosis
Abstract Number: 2487

Cardiovascular and venous thromboembolic events in systemic sclerosis: Epidemiological analysis of the Clinical Practice Research Datalink
Abstract Number: 2488

Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
Abstract Number: 2489

Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum
Abstract Number: 2490

Unmasking Mortality Risk: The Impact of Systemic Sclerosis in Stress-Induced Cardiomyopathy
Abstract Number: 2491

High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study
Abstract Number: 2492

Autoantibody Profiles and Disease Trajectories in Early Systemic Sclerosis: Insights from a Prospective Cohort
Abstract Number: 2493

Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
Abstract Number: 2494

Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
Abstract Number: 2495

IL-6/STAT3 Signaling is Central for Chemokine Production in E2-Induced Dermal Inflammation
Abstract Number: 2496

Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Abstract Number: 2497

Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Abstract Number: 2498

Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].